25 / 25
Page 53
Notes:
allied
academies
February 25-26, 2019 | Paris, France
13
th
World Cancer Congress
Journal of Medical Oncology and Therapeutics | Volume 4
Patient centricity is a concept, not a reality
Nigel Goodman
Gaea OÜ, Estonia
T
hough the industry quoted data on the actual cost of clinical
trials is questionable, it’s clear that despite outsourcing
to CROs clinical research is too slow and expensive. In cancer
specifically, every year multimillions are diagnosed, but only
3-% participate in a clinical trial. For many diseases, a clinical
trial could be a patient’s best chance and is accompanied by
expert care and a full workup.
Patient centricity is a concept, not a reality. Even the FDA state
they want trial design to be driven by patients, to make trials
less burdensome. Patient diversity is also a priority.
Traditional study design still starts from: “How many patients
exist that fit these eligibility criteria?” It’s a good starting
question, but data that patients exist doesn’t mean they
are willing to participate in trials, and we know the common
reasons and they can be more pronounced in biosimilar trials.
The result of ~3-% being willing to join such trials means trials
run slowly.
There are hundreds of apps and database access companies,
but what effects are they having? A fresh approach is needed.
e:
nigel.goodman@gaeaou.com